Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VLV032
MIFTS: 48

Vulva Cancer

Categories: Rare diseases, Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vulva Cancer

About this section

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer 12 15
Vulva Carcinoma 12 55 15
Vulvar Cancer 53 37 43
Malignant Neoplasm of Vulva 12 73
Carcinoma of Vulva 12 73
Vulvar Neoplasms 44 73
Malignant Tumor of Vulva 12
Malignant Vulvar Tumor 12
Neoplasm of Vulva 12
Vulvar Carcinoma 12
Vulval Neoplasm 12
Vulvar Neoplasm 12
Vulval Cancer 12
Vulvar Tumor 12
Ca Vulva 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Vulva Cancer

About this section
MedlinePlus : 43 Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first. However, see your doctor for testing if you notice A lump in the vulva Vulvar itching or tenderness Bleeding that is not your period Changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer You are at greater risk if you've had a human papillomavirus (HPV) infection or have a history of genital warts. Your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. Treatment varies, depending on your overall health and how advanced the cancer is. It might include surgery, radiation therapy, chemotherapy, or biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Vulva Cancer, also known as vulva carcinoma, is related to bartholin's gland benign neoplasm and cervix uteri carcinoma in situ, and has symptoms including pruritus vulvae and pelvic pain. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are L1CAM interactions and Glioblastoma Multiforme. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and skin.

Disease Ontology : 12 A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

NIH Rare Diseases : 53 Vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina.  Symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding.  Though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer.  Treatment may include laser therapy, surgery, chemotherapy, or radiation therapy.

Wikipedia : 76 Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Sources

Related Diseases for Vulva Cancer

About this section

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 bartholin's gland benign neoplasm 32.7 CDKN2A TP53
2 cervix uteri carcinoma in situ 30.7 CDKN2A TP53
3 vulva adenocarcinoma 30.6 CDKN2A KRT7 LINC01191 UPK3A
4 vulva squamous cell carcinoma 30.3 CDKN2A PLXDC2 SERPINB3 SH3GL2 TP53
5 vaginal disease 11.0
6 vulvar disease 11.0
7 brain ependymoma 10.9 EGFR TP53
8 malignant peritoneal mesothelioma 10.9 CDKN2A EGFR
9 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
10 anaplastic oligodendroglioma 10.9 CDKN2A EGFR
11 benign breast adenomyoepithelioma 10.8 EGFR KRT7
12 inverted transitional papilloma 10.8 CDKN2A KRT7
13 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
14 spitz nevus 10.8 CDKN2A TP53
15 oncocytic breast carcinoma 10.8 EGFR KRT7
16 cervical adenosquamous carcinoma 10.8 CDKN2A EGFR
17 breast squamous cell carcinoma 10.8 EGFR TP53
18 thyroid lymphoma 10.8 CDKN2A TP53
19 malignant spiradenoma 10.8 KRT7 TP53
20 bronchiolo-alveolar adenocarcinoma 10.8 EGFR KRT7
21 bone squamous cell carcinoma 10.8 CDKN2A TP53
22 scrotal carcinoma 10.8 CDKN2A TP53
23 mucinous bronchioloalveolar adenocarcinoma 10.8 CDKN2A KRT7
24 female reproductive endometrioid cancer 10.8 KRT7 TP53
25 endocervical carcinoma 10.8 CDKN2A KRT7
26 adenoid basal cell carcinoma 10.8 CDKN2A KRT7
27 anal squamous cell carcinoma 10.8 CDKN2A TP53
28 gastric adenosquamous carcinoma 10.8 CDKN2A TP53
29 microglandular adenosis 10.8 EGFR TP53
30 eccrine sweat gland neoplasm 10.8 KRT7 TP53
31 oral leukoplakia 10.8 CDKN2A TP53
32 anogenital venereal wart 10.8 CDKN2A TP53
33 megaesophagus 10.8 CDKN2A TP53
34 schneiderian carcinoma 10.7 CDKN2A TP53
35 papillary serous adenocarcinoma 10.7 KRT7 TP53
36 pulmonary blastoma 10.7 EGFR TP53
37 spiradenoma 10.7 KRT7 TP53
38 meningeal melanomatosis 10.7 CDKN2A TP53
39 dedifferentiated liposarcoma 10.7 CDKN2A TP53
40 gliomatosis cerebri 10.7 EGFR TP53
41 well-differentiated liposarcoma 10.7 CDKN2A KRT7
42 suppressor of tumorigenicity 3 10.7 CDKN2A TP53
43 soft tissue sarcoma 10.7 EGFR TP53
44 renal pelvis transitional cell carcinoma 10.7 KRT7 UPK3A
45 non-invasive bladder papillary urothelial neoplasm 10.7 TP53 UPK3A
46 esophageal basaloid squamous cell carcinoma 10.7 EGFR TP53
47 invasive bladder transitional cell carcinoma 10.7 TP53 UPK3A
48 biliary papillomatosis 10.7 KRT7 TP53
49 glandular cystitis 10.7 KRT7 UPK3A
50 lymphoid interstitial pneumonia 10.7 KRT13 TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Clitoris Cancer
Hypertension, Essential Localized Scleroderma
Vaginal Cancer Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:



Diseases related to Vulva Cancer
Sources

Symptoms & Phenotypes for Vulva Cancer

About this section

UMLS symptoms related to Vulva Cancer:


pruritus vulvae, pelvic pain
Sources

Drugs & Therapeutics for Vulva Cancer

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
5
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
6 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
7 Liver Extracts Phase 3,Phase 2,Phase 1
8 Coagulants Phase 3
9 Fibrin Tissue Adhesive Phase 3
10 Hemostatics Phase 3
11 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Hormonal Phase 3
13 Gastrointestinal Agents Phase 3,Phase 1
14 Adjuvants, Anesthesia Phase 3
15 Analgesics Phase 3,Phase 2
16 Analgesics, Opioid Phase 3
17 Anesthetics Phase 3
18 Anesthetics, General Phase 3
19 Anesthetics, Intravenous Phase 3
20 Central Nervous System Depressants Phase 3
21 Narcotics Phase 3
22 Peripheral Nervous System Agents Phase 3,Phase 2
23 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
24 Cola Nutraceutical Phase 3,Phase 2,Phase 1
25 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Clobetasol Approved, Investigational Phase 2 25122-46-7, 25122-41-2 32798 5311051
31
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
32
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
33 Fondaparinux Approved, Investigational Phase 2 104993-28-4
34
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
35
Imiquimod Approved, Investigational Phase 2,Not Applicable 99011-02-6 57469
36
nivolumab Approved Phase 2,Phase 1 946414-94-4
37
Daratumumab Approved Phase 1, Phase 2 945721-28-8
38
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
39
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
40
Fludarabine Approved Phase 1, Phase 2,Phase 2 21679-14-1, 75607-67-9 30751
41
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
42
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
43
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
44
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
45
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
46
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
47
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
48 Anti-HIV Agents Phase 2,Phase 1
49 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
50 Anti-Retroviral Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Completed NCT00003325 Phase 3
2 Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Completed NCT00898352 Phase 3
3 Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed NCT00028951 Phase 3 fibrin sealant
4 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Completed NCT00224744 Phase 3
5 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
6 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
7 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
8 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
9 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
10 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
11 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
14 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
15 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Recruiting NCT03546842 Phase 3
16 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Active, not recruiting NCT03158220 Phase 3
17 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
18 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
19 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva Terminated NCT00006096 Phase 3 cisplatin
20 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
21 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
22 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
23 Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva Completed NCT00014599 Phase 2 paclitaxel
24 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Completed NCT00068406 Phase 2 Cisplatin
25 The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence Completed NCT01986725 Phase 2
26 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar Completed NCT00476476 Phase 2 Erlotinib
27 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
28 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
29 Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Completed NCT00393263 Phase 2 pimecrolimus and clobetasol;clobetasol 0.05% cream
30 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
31 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
32 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
33 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
34 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
35 Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
36 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
37 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
38 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
39 Image-Guided Gynecologic Brachytherapy Recruiting NCT02993900 Phase 2
40 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 aldesleukin;fludarabine;cyclophosphamide
41 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
42 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
43 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) Recruiting NCT03180684 Phase 2 Imiquimod 5% cream
44 Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Active, not recruiting NCT01406769 Phase 2
45 Image-Guided Gynecologic Brachytherapy Active, not recruiting NCT01399658 Phase 2
46 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Not yet recruiting NCT03220009 Phase 2
47 Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Terminated NCT00003525 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
49 Sentinel Node in Ovarian Cancer Unknown status NCT01734746 Phase 1
50 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Sources

Genetic Tests for Vulva Cancer

About this section
Sources

Anatomical Context for Vulva Cancer

About this section

MalaCards organs/tissues related to Vulva Cancer:

41
Lymph Node, Testes, Skin, Cervix, T Cells, Brain, Prostate
Sources

Publications for Vulva Cancer

About this section

Articles related to Vulva Cancer:

(show all 16)
# Title Authors Year
1
Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. ( 29420364 )
2018
2
Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? ( 28034465 )
2017
3
Vulva cancer in Ghana - Review of a hospital based data. ( 28409179 )
2017
4
The Added Value of Pathology Review in Vulva Cancer: Results From a Population-based Cohort Study. ( 27513080 )
2016
5
Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )
2014
6
Could Sentinel Node Mapping of the Groin Cause Extranodal Metastasis in Vulva Cancer? ( 25412581 )
2014
7
Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )
2013
8
The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )
2012
9
Assessment of promising protein markers for vulva cancer. ( 19509584 )
2009
10
An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )
2006
11
Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )
2005
12
Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )
2002
13
Inguinal node status by ultrasound in vulva cancer. ( 10739696 )
2000
14
Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )
1996
15
T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )
1995
16
Adenocarcinoma of the mammary-like glands of the vulva: a concept unifying sweat gland carcinoma of the vulva, carcinoma of supernumerary mammary glands and extramammary Paget's disease. ( 8040464 )
1994
Sources

Variations for Vulva Cancer

About this section

Cosmic variations for Vulva Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM498 HRAS skin,genital,carcinoma,NS c.182A>T p.Q61L 11:533874-533874 7
2 COSM12296 TP53 skin,lip,carcinoma,NS c.292C>T p.P98S 17:7676077-7676077 6
3 COSM10662 TP53 skin,lip,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
4 COSM17598 PTCH1 skin,lip,carcinoma,NS c.550C>T p.Q184* 9:95485719-95485719 6
5 COSM26363 PTCH1 skin,lip,carcinoma,NS c.2446C>T p.Q816* 9:95467230-95467230 6
Sources

Expression for Vulva Cancer

About this section
Search GEO for disease gene expression data for Vulva Cancer.
Sources

Pathways for Vulva Cancer

About this section

Pathways related to Vulva Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
L1CAM interactions 66
Show member pathways
 11.53 EGFR SCN10A SH3GL2
2
Glioblastoma Multiforme 64
11.38 CDKN2A EGFR TP53
3
Gastric Cancer Network 2 1
10.95 EGFR TP53
4
Oncogene Induced Senescence 66
10.91 CDKN2A TP53
5
Photodynamic therapy-induced AP-1 survival signaling. 1
10.84 CDKN2A EGFR TP53
6
Bladder cancer 37 1
10.79 CDKN2A EGFR TP53 UPK3A
7
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.71 CDKN2A TP53
8
TP53 Network 1
Show member pathways
 10.66 CDKN2A TP53
Sources

GO Terms for Vulva Cancer

About this section

Cellular components related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 KRT13 KRT7 PLXDC2 SCN10A SERPINB3 SH3GL2

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 8.96 EGFR SH3GL2
2 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 8.92 CDKN2A EGFR SH3GL2 TP53
Sources

Sources for Vulva Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....